All In Biotech

Drug Trial Radar · NCT07819136

REC-7735 in Participants With Solid Tumors

A Phase 1 / 2, Open-Label Study of REC-7735 in Participants With Unresectable, Locally Advanced, or Metastatic PIK3CA-H1047R Mutated Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Jan 2031

Study completion Jan 2031

Sponsor

Lead sponsor
Recursion Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Sep 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of REC-7735 in participants with unresectable, locally advanced, or metastatic PIK3CA-H1047R mutated solid tumors.

Conditions

  • Solid Tumors

Interventions

  • REC-7735Drug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1A: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: 28 days
  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 2 years
  3. Phase 1B: Objective Response Rate (ORR) According to Standard Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: Up to 2 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • NEXT Oncology - Dallas

    Irving, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.